Related Topics News -

     
 Title only   |   Print 
     
內地發布健全藥品價格形成機制 優化創新藥等首發價格機制

2026-04-15T  
國家藥監局:首季創新藥對外授權交易額逾600億美元

2026-03-30T  
《大行》招銀國際升藥明生物目標價至39元 續予「買入」評級

2026-03-27T  
《大行》瑞銀下調藥明生物今明兩年每股盈利預測 微降目標價至49.3元

2026-03-26T  
《大行》中金升藥明生物目標價至48元 維持「跑贏行業」評級

2026-03-26T  
《大行》美銀證券降藥明生物目標價至39.5元 評級「中性」

2026-03-26T  
《大行》野村:藥明生物維持「買入」評級 目標價50.54元

2026-03-25T  
《藍籌》藥明生物全年純利升46.3%至49.08億人幣 經調整純利升17.9%

2026-03-24T  
王文濤與美國PhRMA及和跨國醫企負責人就在華發展進行交流

2026-03-23T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.